![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1782123
Áý¼Ó ÃÊÀ½ÆÄ ½Ã½ºÅÛ ½ÃÀå : ½ÃÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®, ¿¹Ãø(2025-2034³â)Focused Ultrasound Systems Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 |
¼¼°èÀÇ Áý¼Ó ÃÊÀ½ÆÄ ½Ã½ºÅÛ ½ÃÀåÀº 2024³â¿¡ 2¾ï 6,440¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, CAGR 9.4%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 2034³â¿¡´Â 6¾ï 4,240¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, ±â¼úÀÇ Áøº¸, ºñħ½ÀÀû Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ÀÔ´Ï´Ù. Áý¼Ó ÃÊÀ½ÆÄ ½Ã½ºÅÛ-ƯÈ÷ °í°µµ Áý¼Ó ÃÊÀ½ÆÄ(HIFU)¿Í Àú°µµ Áý¼Ó ÃÊÀ½ÆÄ(LIFU)´Â Á¤È®µµ, ¾ÈÀü¼º, ¼ö¼úÀ» ÇÊ¿ä·Î ÇÏÁö ¾Ê°í ´Ù¾çÇÑ º´¼¼¸¦ Ä¡·áÇÏ´Â ´É·ÂÀ¸·Î Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ¾Ï ÀÌȯÀ²ÀÇ »ó½Â, Àα¸ÀÇ °í·ÉÈ, ¿Ü·¡ ȯÀÚ Ã³Ä¡¿¡ ´ëÇÑ È¯ÀÚÀÇ ±âÈ£°¡, º´¿ø, È»ó Áø´Ü ¼¾ÅÍ, ¿¬±¸ ±â°ü Àüü¿¡¼ ÀÌ·¯ÇÑ ½Ã½ºÅÛÀÇ Ã¤¿ëÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.
¶ÇÇÑ Á¾¾çÇÐ, ºÎÀΰúÇÐ, ½Å°æÇп¡¼ HIFUÀÇ ÀÓ»óÀû È¿´ÉÀº ±âÁ¸ÀÇ ¼ö¼ú ¹æ¹ý¿¡ ºñÇØ ÁÖº¯ °Ç°ÇÑ ±¸Á¶¹°¿¡ ´ëÇÑ ¼Õ»óÀ» ÃÖ¼ÒÈÇϰí ȸº¹ ½Ã°£À» ´ÜÃàÇϸç ÇÕº´ÁõÀ» ÁÙÀÎ Á¤È®ÇÑ Á¶Á÷ ÀýÁ¦ ¸¦ Á¦°øÇϱâ À§ÇØ È¯ÀÚ¿Í °³¾÷ÀÇ ¾çÂÊ ¸ðµÎ°¡ ¹Þ¾ÆµéÀÌ´Â ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. Á¾¾çÇп¡¼ HIFU´Â Àü¸³¼±, °£, À¯¹æÀÇ Çѱ¹¼º Á¾¾çÀÇ Ä¡·á¿¡ ƯÈ÷ À¯¿ëÇϰí, ºñħ½ÀÀûÀ¸·Î ¾Ï Á¶Á÷À» Ç¥ÀûÀ¸·Î ÇÏ´Â ±× ´É·ÂÀº °¨ ¿°Áõ, ÃâÇ÷ ¹× Àå±â ºÎÀÛ¿ëÀÇ À§ÇèÀ» ³·Ãß´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ºÎÀΰú ºÎÀ§¿¡¼ HIFU´Â Àڱà ±ÙÁ¾°ú Àڱà ¼±±ÙÁõÀ» Ä¡·áÇÏ´Â µ¥ ¼±È£µÇ´Â ¼±ÅÃÀ̸ç, ¿©¼º¿¡°Ô Àڱà ÀûÃâÀ» ´ëüÇÏ´Â Àӽżº ¿ÂÁ¸ ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ½Å°æÇÐ ºÐ¾ß¿¡¼´Â MRI °¡À̵å ÇÏ¿¡ HIFU°¡ º»Å¼º ÁøÀüÀ̳ª ÆÄŲ½¼º´ÀÇ °ü¸®¿¡ ä¿ëµÇ°í ÀÖ¾î ħ½ÀÀûÀÎ ³ú ¼ö¼úÀ» ÇÊ¿ä·Î ÇÏÁö ¾Ê°í ÁøÀüÀ» ÄÁÆ®·ÑÇÒ ¼ö ÀÖ°Ô µÇ¾î ÀÖ½À´Ï´Ù.
½ÃÀå ¹üÀ§ | |
---|---|
½ÃÀÛ ¿¬µµ | 2024³â |
¿¹Ãø ¿¬µµ | 2025-2034³â |
½ÃÀÛ ±Ý¾× | 2¾ï 6,440¸¸ ´Þ·¯ |
¿¹Ãø ±Ý¾× | 6¾ï 4,240¸¸ ´Þ·¯ |
CAGR | 9.4% |
Áý¼Ó ÃÊÀ½ÆÄ ½Ã½ºÅÛ ½ÃÀåÀº ÁÖ·Î Á¦Ç° À¯Çüº°·Î ±¸ºÐµÇ¸ç, 2024³âÀº °í°µµ ÃÊÁ¡½Ä ÃÊÀ½ÆÄ(HIFU) ½Ã½ºÅÛÀÌ 2¾ï 6,080¸¸ ´Þ·¯¸¦ ¹ú¾î ½ÃÀå Á¡À¯À² ÀüüÀÇ 98.6%¸¦ Â÷ÁöÇØ ÅéÀ̾ú½À´Ï´Ù. HIFU ½Ã½ºÅÛÀº ¿¿¡³ÊÁö¸¦ »ç¿ëÇÏ¿© Á¶Á÷À» Á¤È®ÇÏ°Ô ÀýÁ¦ÇÏ´Â ´É·ÂÀ¸·Î ³Î¸® ÀÌ¿ëµÇ°í ÀÖÀ¸¸ç Àü¸³¼±¾Ï, ÀڱñÙÁ¾, ±âŸ Á¾¾çÀÇ Ä¡·á ¿ëµµ¿¡ ÀÌ»óÀûÀÔ´Ï´Ù. ±× ºñħ½À¼º, ÃÖ¼ÒÇÑÀÇ È¸º¹ ½Ã°£, °íÁ¤¹ÐÀº, °¢ Áö¿ª¿¡¼ ÀÓ»óÀû °ü½ÉÀÇ °íÁ¶¿Í ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ» ¸ðÀ¸°í ÀÖ½À´Ï´Ù. MRI³ª ÃÊÀ½ÆÄ °¡À̵å ÇÏ¿¡ HIFU µîÀÇ ±â¼ú Çõ½Å ¶ÇÇÑ, ¼Õ±â¼úÀÇ ¾ÈÀü¼ºÀ» ³ô¿© °£, ½ÅÀå, À¯¹æ¾Ï Ä¡·á µîÀÇ ÀûÀÀÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù.
¿ëµµº°·Î´Â ÀÓ»ó ¿ëµµ ºÐ¾ß´Â 2024³â¿¡ 2¾ï 5,960¸¸ ´Þ·¯¸¦ âÃâÇß°í, Á¾¾çÇÐ, ºÎÀΰú, ½Å°æÇп¡ °ÉÄ£ Àúħ½À óġ ¼ö¿ä Áõ°¡°¡ ±× ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ½Ç½Ã°£ À̹Ì¡°ú ¿¡³ÊÁö °ø±Þ ¸ÞÄ¿´ÏÁò¿¡¼ÀÇ Çõ½ÅÀº Àü¸³¼±¾Ï Ä¡·áÀÇ Á¤È®µµ¿Í °á°ú¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ¿Í º´ÇàÇÏ¿© LIFU ±â¼úÀº º»Å¼º ÁøÀüÀÇ °ü¸®¿Í ºñħ½ÀÀûÀÎ ½Å°æÁ¶ÀýÀ» À§ÇØ ¿¬±¸µÇ°í ÀÖÀ¸¸ç, ½Å°æÁúȯ ¹× Á¤½ÅÁúȯ¿¡ ´ëÇÑ »õ·Î¿î Ä¡·á¼ö´ÜÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù.
ÃÖÁ¾ ¿ëµµº°·Î º´¿ø ºÎ¹®Àº 2024³â¿¡ 1¾ï 6,450¸¸ ´Þ·¯¸¦ âÃâÇß°í, ±¤¹üÀ§ÇÑ ÀÎÇÁ¶ó¿Í ȯÀÚ ÄÉ¾î ¿öÅ©Ç÷ο쿡 ÅëÇÕµÈ Áý¼Ó ÃÊÀ½ÆÄ ±â¼úÀÇ ÇýÅÃÀ» ¹Þ°í ÀÖ½À´Ï´Ù. º´¿øÀº, º¹ÀâÇÑ Ä¡·á¸¦ ¼Æ÷Æ®ÇØ, °¡À̵å ÷ºÎ óġ¿¡ ºÒ°¡°áÇÑ °íµµÀÇ À̹Ì¡ ±â´ÉÀ» Á¦°øÇÒ ¼ö Àֱ⠶§¹®¿¡, ÀÓ»ó µµÀÔÀÇ ÁÖ¿äÇÑ ÃßÁø¿ªÀÌ µÇ°í ÀÖ½À´Ï´Ù. Àúħ½ÀÀ¸·Î ¿Ü·¡È¯ÀÚ ±â¹ÝÀÇ °³ÀÔ¿¡ ´ëÇÑ ±âÈ£°¡ ³ô¾ÆÁö´Â °ÍÀº ƯÈ÷ Á¾¾çÇÐ, ½Å°æÇÐ, ¿©¼ºÀÇ °Ç° ¾ÖÇø®ÄÉÀ̼ÇÀ» À§ÇØ º´¿øÀÌ HIFU¿Í LIFU µÎ Ç÷§Æû¿¡ ÅõÀÚÇϵµ·Ï µ¶·ÁÇϰí ÀÖ½À´Ï´Ù. È»ó Áø´Ü ¼¾Åͳª ¿¬±¸ ±â°üµµ, Áø´Ü À¯µµ Ä¡·á³ª ÀÓ»ó ½ÃÇè¿¡ ÀÌ·¯ÇÑ ½Ã½ºÅÛÀ» Ȱ¿ëÇØ ¼ºÀå¿¡ °øÇåÇϰí ÀÖ½À´Ï´Ù.
ºÏ¹ÌÀÇ Áý¼Ó ÃÊÀ½ÆÄ ½Ã½ºÅÛ 2024³â ½ÃÀå ±Ô¸ð´Â 1¾ï 370¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, ¼º¼÷ÇÑ ÇコÄÉ¾î ¿¡ÄڽýºÅÛ, Á¶±â ±â¼ú µµÀÔ, ȯÀÚÀÇ ³ôÀº ÀÎÁöµµ°¡ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹¿¡¼´Â À¯¸®ÇÑ »óȯ Á¤Ã¥ ¹× ÁöÁöÀûÀÎ ±ÔÁ¦ ȯ°æÀ¸·Î ÀÎÇØ Á¾¾çÇÐ ¹× ºñ´¢±âÇп¡ HIFU ½Ã½ºÅÛ µµÀÔÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. À¯·´ÀÌ ÀÌ¿¡ ÀÌ¾î µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º µîÀÇ ±¹°¡µéÀÇ °·ÂÇÑ ¼ö¿ä°¡ ÀÖ½À´Ï´Ù.
Áý¼Ó ÃÊÀ½ÆÄ ½Ã½ºÅÛ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº Insightec Ltd., EDAP TMS SA, Profound Medical Corp., Chongqing Haifu Medical Technology Co.Ltd., ILJIN Holdings Co.Ltd. µîÀÌ ÀÖ½À´Ï´Ù. ÀÌ È¸»ç´Â ¿¬±¸ °³¹ß, ¾à»ç ½ÂÀÎ, Àü·«Àû ÆÄÆ®³Ê½Ê¿¡ ´ëÇÑ ³ë·ÂÀ» °ÈÇϰí Á¦Ç° Æ÷Æ®Æú¸®¿À ¹× ½ÃÀå¿¡¼ÀÇ Á¸À縦 È®´ëÇÏ·Á°í ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. Æ÷Åͺí HIFU ÀåÄ¡, °ÈµÈ À̹ÌÁö ÅëÇÕ, ºñ¾Ï »óÅ ¿ëµµ µîÀÇ Çõ½ÅÀº Áý¼Ó ÃÊÀ½ÆÄ ±â¼úÀÇ ÀÓ»óÀû À¯¿ë¼º°ú »ó¾÷Àû ½ÇÇà °¡´É¼ºÀ» ´õ¿í È®´ëÇϰí ÀÖ½À´Ï´Ù. º¸´Ù ¾ÈÀüÇϰí, º¸´Ù ½Å¼ÓÇϰí, º¸´Ù È¿°úÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó Áý¼Ó ÃÊÀ½ÆÄ ½Ã½ºÅÛÀº Á¤¹ÐÀÇ·á ¹× ºñħ½ÀÀû Ä¡·áÀÇ ÁøÈ¿¡ Ãʼ®ÀÌ µÉ ¼ö ÀÖµµ·Ï ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù
The Global Focused Ultrasound Systems Market was valued at USD 264.4 million in 2024 and is estimated to grow at a CAGR of 9.4% to reach USD 642.4 million by 2034. The market growth is driven by the increasing prevalence of chronic diseases, technological advancements, and the growing demand for non-invasive therapeutic solutions. Focused ultrasound systems-particularly high-intensity focused ultrasound (HIFU) and low-intensity focused ultrasound (LIFU)-are gaining traction due to their precision, safety, and ability to treat various medical conditions without the need for surgery. Rising cancer rates, aging populations, and patient preference for outpatient procedures are accelerating the adoption of these systems across hospitals, imaging centers, and research institutions.
Moreover, HIFU's clinical efficacy in oncology, gynecology, and neurology is driving both patient and practitioner acceptance, as it offers precise tissue ablation with minimal damage to surrounding healthy structures, reduced recovery time, and fewer complications compared to traditional surgical methods. In oncology, HIFU is proving especially valuable in treating localized prostate, liver, and breast tumors, where its ability to target cancerous tissues non-invasively helps lower the risk of infection, bleeding, and long-term side effects. In gynecology, HIFU has become a preferred option for the treatment of uterine fibroids and adenomyosis, providing women with a fertility-preserving alternative to hysterectomy. In the field of neurology, MRI-guided HIFU is being increasingly adopted for the management of essential tremor and Parkinson's disease, offering tremor control without the need for invasive brain surgery.
Market Scope | |
---|---|
Start Year | 2024 |
Forecast Year | 2025-2034 |
Start Value | $264.4 Million |
Forecast Value | $642.4 Million |
CAGR | 9.4% |
The focused ultrasound systems market is primarily segmented by product type, with high-intensity focused ultrasound (HIFU) systems leading in 2024, generating USD 260.8 million and accounting for 98.6% of the total market share. HIFU systems are widely utilized for their capability to precisely ablate tissue using thermal energy, making them ideal for applications in treating prostate cancer, uterine fibroids, and other tumors. Their non-invasive nature, minimal recovery time, and high accuracy are attracting increasing clinical interest and regulatory approvals across regions. Technological innovations such as MRI- and ultrasound-guided HIFU are also enhancing procedure safety and expanding indications, including liver, kidney, and breast cancer treatments.
In terms of application, the clinical applications segment generated USD 259.6 million in 2024, driven by the growing demand for minimally invasive procedures across oncology, gynecology, and neurology. Innovations in real-time imaging and energy delivery mechanisms are improving the accuracy and outcomes of prostate cancer treatments. In parallel, LIFU technologies are being explored in the management of essential tremors and for non-invasive neuromodulation, offering new therapeutic avenues for neurological and psychiatric disorders.
By end use, the hospitals segment generated USD 164.5 million in 2024, benefiting from extensive infrastructure and integrated focused ultrasound technologies into patient care workflows. Hospitals are key drivers in clinical adoption due to their ability to support complex therapies and offer advanced imaging capabilities essential for guided procedures. The growing preference for minimally invasive and outpatient-based interventions is encouraging hospitals to invest in both HIFU and LIFU platforms, especially for oncology, neurology, and women's health applications. Imaging centers and research institutions are also contributing to growth, leveraging these systems for diagnostic-guided therapy and clinical trials.
North America Focused Ultrasound Systems Market generated USD 103.7 million in 2024, bolstered by a mature healthcare ecosystem, early technology adoption, and high patient awareness. The U.S. has seen increased deployment of HIFU systems in oncology and urology due to favorable reimbursement policies and supportive regulatory environments. Europe follows closely, with strong demand from countries like Germany, the UK, and France.
Leading companies in the Focused Ultrasound Systems Market include Insightec Ltd., EDAP TMS S.A., Profound Medical Corp., Chongqing Haifu Medical Technology Co., Ltd., and ILJIN Holdings Co., Ltd. These firms are intensifying their efforts in R&D, regulatory approvals, and strategic partnerships to expand their product portfolios and market presence. Innovations such as portable HIFU devices, enhanced imaging integration, and applications in non-cancerous conditions are further expanding the clinical utility and commercial viability of focused ultrasound technologies. As the demand for safer, faster, and more effective therapeutic options grows, focused ultrasound systems are positioned to become a cornerstone in the evolution of precision medicine and non-invasive care.